Another study reported that APOC1 could reduce iron death in non-small cell lung cancer (NSCLC) patients through the NRF2/HO-1 pathway, which in turn inhibited the conversion of M2 to M1 macrophages for anti-PD-1 immunotherapy for NSCLC [22]. This evidence concerns the gene APOC1 and non-small cell lung carcinoma.